Skip to main content

Table 4 Subgroup analysis of potential preditive factors of overall survival did not identify any specific subgroup to benefit from either NFRT compared to AHFRT or vice versa

From: Accelerated hyperfractionation plus temozolomide in glioblastoma

  

Median OS [m]

  

NFRT

AHFRT

p

Variable

   

Age

< median of 61 years

15

12

0.66

 

> = median of 61 years

15

9

0.28

Gender

m

14

9

0.31

 

f

16

14

0.98

KPS

< median of 70 %

12

6

0.16

 

> = median of 70 %

15

13

0.67

MGMT-status

methylated

16

15

0.73

 

unmethylated

14

9

0.09

Localization

other

15

10

0.41

 

central

9

17

0.44

PTV

< median of 337 ccm

15

12

0.82

 

> = median of 337 ccm

15

9

0.24

Extent of resection

Subtotal resection or biopsy

13

8

0.14

 

gross total resection

15

13

0.6

  1. KPS Karnofsky performance status, MGMT O-6-methylguanine-DNA methyltransferase, PTV planning target volume, NFRT normofractionated radiotherapy, AHFRT accelerated hyperfractionated radiotherapy